세계의 올리고뉴클레오티드 CDMO 시장 : 서비스 유형별, 유형별, 용도별, 최종사용자별, 지역별 - 예측(-2029년)

The global oligonucleotide CDMO market is projected to reach USD 6.73 billion in 2029 from USD 2.51 billion in 2024, with a CAGR of 21.8% during the forecast period. Key factors driving market growth include increasing focus on the launch of novel oligo-based drugs and growing outsourcing to CDMOs. Oligonucleotides, such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers, are being focused on due to the specificity and targeted action offered by these drugs. This has led to an increase in development activity followed by FDA approvals. For instance, in April 2023, Qalsody (tofersen) was approved by the US FDA for treating amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Additionally, expertise and lower costs incurred while outsourcing clinical development and manufacturing (clinical and commercial) further support the growth of this market.

"The contract manufacturing segment accounted for the largest share in the oligonucleotide CDMO market, by service type, in 2023"

In 2023, contract manufacturing segment accounted for the largest share of the oligonucleotide CDMO market. Factors such as expertise offered by CDMOs leading to the reduction in production timelines and improving production scalability, supported by an increase in the demand for oligonucleotide therapeutics are supporting the growth of this segment. Additionally, regulatory expertise offered by CDMOs further reduces time-to-market and operational risks is another factor driving the outsourcing of manufacturing to CDMOs.

"The pharmaceutical and biotechnology companies end-user segment registered the highest growth rate and largest market share in the oligonucleotide CDMO market, by end user, during the forecast period"

Pharmaceutical and biotechnology companies are major end user segments of the oligonucleotide CDMO market. The increasing clinical and commercial demand for oligo-based therapies drives pharma and biotech companies to engage CDMOs for production. Oligonucleotide synthesis is complex and requires specialized expertise, high-end technologies, and regulatory compliance. CDMOs have established infrastructure and systems in place for offering to these companies. Thus, pharmaceutical and biotechnology companies largely rely on CDMOs, mainly for manufacturing, fill-finish, and other services.

"Asia Pacific: The fastest growing region in the oligonucleotide CDMO market"

Asia Pacific region, with countries like China, India, Japan, and South Korea are experiencing rapid growth in their biopharmaceutical industries, with increased focus on innovative therapies such as oligonucleotide-based drugs. Additionally, the Asia Pacific region offers significant cost advantages for CDMO services due to lower labor, production, and operational costs. This is attracting global players to outsource manufacturing activities from the Asia Pacific region.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Supply Side - 65% and Demand Side - 35%
• By Designation: (Managers) - 45%, (CXOs, Directors)- 30%, and(Executives) - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, Middle East & Africa - 5%

List of Companies Profiled in the Report:

• Bachem (Switzerland)
• Thermo Fisher Scientific Inc. (US)
• Agilent Technologies, Inc. (US)
• Maravai Lifesciences (US)
• GenScript (US)
• Wuxi Apptec (China)
• Eurofins Scientific (Luxembourg)
• Lonza (Switzerland)
• Danaher Corporation (US)
• Syngene International Limited (US)
• EUROAPI (France)
• Ajinomoto Co., Inc. (Japan)
• ST Pharm (South Korea)
• Kaneka Corporation (Japan)
• Aurigene Pharmaceutical Services Ltd. (India)
• PolyPeptide Group (Switzerland)
• Biospring (Germany)
• Oligo factory (US)
• Corden Pharma (Switzerland)
• LGC Biosearch Technologies (UK)
• Bio-Synthesis Inc (US)
• Microsynth (Switzerland)
• Synoligo Biotechnologies, Inc. (US)
• Hongene Biotech Corporation (China)
• Sylentis, S.A. (Spain)
• Creative Biogene. (US)

Research Coverage:

This report provides a detailed picture of the global oligonucleotide CDMO Market. It aims to estimate the size and future growth potential of the market across different segments such as service type, stage, type, application, end users and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide CDMO market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, mergers and acquisitions, and recent developments associated with the protein expression market. Competitive analysis of upcoming startups in the oligonucleotide CDMO market ecosystem is covered in this report.

Reasons to buy this report :

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall oligonucleotide CDMO market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing focus on development and commercialization of oligo-based therapeutics), restraints (Complexities associated with oligonucleotide manufacturing ), opportunities (Increasing use of oligos for CRISPR/Cas 9 application), and challenges (Lack of sustainable and eco-friendly supply chain) influencing the growth of the oligonucleotide CDMO market.
• Innovation: Detailed insights on upcoming technologies, research & development activities, in the oligonucleotide CDMO market
• Market Development: Comprehensive information about lucrative markets - the report analyses the oligonucleotide CDMO market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the oligonucleotide CDMO market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players in the oligonucleotide CDMO market like- Bachem (Switzerland), Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), EUROAPI (France), ST Pharm (South Korea), Wuxi Apptec (China), Maravai Lifesciences (US), and Biospring (Germany) among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED & REGIONS CONSIDERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 OLIGONUCLEOTIDE CDMO MARKET OVERVIEW
• 4.2 NORTH AMERICA: OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE & COUNTRY (2023)
• 4.3 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE, 2024 VS 2029
• 4.4 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION, 2024 VS 2029
• 4.5 OLIGONUCLEOTIDE CDMO MARKET SHARE, BY END USER, 2023
• 4.6 OLIGONUCLEOTIDE CDMO MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing focus on development and commercialization of oligo-based therapeutics
    • 5.2.1.2 Advantages of contract development and manufacturing
    • 5.2.1.3 Increasing focus on precision/personalized medicine
    • 5.2.1.4 Technological advancements
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Complexities associated with therapeutic oligonucleotide manufacturing
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing use of oligos in CRISPR-Cas9 applications
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Lack of sustainable and eco-friendly supply chain
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
• 5.4 SUPPLY CHAIN ANALYSIS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ROLE IN ECOSYSTEM
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Process technologies
      • 5.7.1.1.1 Solid-phase synthesis
      • 5.7.1.1.2 Liquid-phase synthesis
      • 5.7.1.1.3 Enzymatic oligo synthesis
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Purification, analysis, and quality control technologies
      • 5.7.2.1.1 Chromatography
      • 5.7.2.1.2 Mass spectrometry
    • 5.7.2.2 Other technologies
      • 5.7.2.2.1 Polymerase chain reaction (PCR)
      • 5.7.2.2.2 Next-generation sequencing
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 3D printing
• 5.8 PRICING ANALYSIS
  • 5.8.1 INDICATIVE PRICE OF OLIGONUCLEOTIDE CDMO SERVICES, BY KEY PLAYER
  • 5.8.2 AVERAGE SELLING PRICE, BY REGION (QUALITATIVE)
• 5.9 KEY CONFERENCES & EVENTS IN 2024-2025
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 REGULATORY FRAMEWORK
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 DEGREE OF COMPETITION
  • 5.11.2 BARGAINING POWER OF SUPPLIERS
  • 5.11.3 BARGAINING POWER OF BUYERS
  • 5.11.4 THREAT OF SUBSTITUTES
  • 5.11.5 THREAT OF NEW ENTRANTS
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE CDMO SERVICES
• 5.13 KEY BUYING CRITERIA
• 5.14 INVESTMENT & FUNDING SCENARIO
• 5.15 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE CDMO MARKET

6 OLIGONUCLEOTIDE CDMO MARKET, BY SERVICE TYPE

• 6.1 INTRODUCTION
• 6.2 CONTRACT MANUFACTURING
  • 6.2.1 COMMERCIAL STAGE
    • 6.2.1.1 Flexible, scalable production facilities to propel market growth
  • 6.2.2 CLINICAL STAGE
    • 6.2.2.1 Growing demand for oligonucleotide-based therapeutics to drive market
• 6.3 CONTRACT DEVELOPMENT
  • 6.3.1 GROWING FOCUS ON REDUCING MANUFACTURING RISKS TO SUPPORT MARKET GROWTH
• 6.4 OTHER SERVICES

7 OLIGONUCLEOTIDE CDMO MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 ANTISENSE OLIGONUCLEOTIDES
  • 7.2.1 SPECIFIC DEVELOPMENT & MANUFACTURING REQUIREMENTS WELL-SUPPORTED BY CDMOS TO DRIVE MARKET GROWTH
• 7.3 SMALL INTERFERING RNA
  • 7.3.1 POTENTIAL IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET GROWTH
• 7.4 OTHER OLIGONUCLEOTIDES

8 OLIGONUCLEOTIDE CDMO MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 THERAPEUTIC APPLICATIONS
  • 8.2.1 GROWING DEMAND FOR OLIGONUCLEOTIDE-BASED THERAPEUTICS TO DRIVE MARKET GROWTH
• 8.3 RESEARCH APPLICATIONS
  • 8.3.1 USE OF OLIGOS IN SEQUENCING FOR ADVANCING DRUG DEVELOPMENT TO SUPPORT GROWTH
• 8.4 DIAGNOSTIC APPLICATIONS
  • 8.4.1 GROWING APPLICATIONS IN MOLECULAR DIAGNOSTICS AND IVD TO PROPEL MARKET

9 OLIGONUCLEOTIDE CDMO MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.2.1 INCREASED INVESTMENTS IN OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT MARKET GROWTH
• 9.3 DIAGNOSTIC COMPANIES
  • 9.3.1 GROWTH OF PERSONALIZED DIAGNOSTICS TO PROPEL MARKET
• 9.4 OTHER END USERS

10 OLIGONUCLEOTIDE CDMO MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Rising approvals of oligonucleotide-based drugs to support market growth
  • 10.2.3 CANADA
    • 10.2.3.1 Government initiatives to drive market growth in Canada
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Academic-industry collaborations to drive market
  • 10.3.3 UK
    • 10.3.3.1 Strategic investments in biomanufacturing to boost market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Focus on advanced biologics manufacturing to drive market
  • 10.3.5 ITALY
    • 10.3.5.1 Increasing focus on biotechnology innovation to boost market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Strategic investments in biotechnology to support market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Government-backed Initiatives and expansion of major companies to strengthen biotechnology sector in China
  • 10.4.3 JAPAN
    • 10.4.3.1 Increased investment in oligonucleotide research and manufacturing to boost market
  • 10.4.4 INDIA
    • 10.4.4.1 Rapidly expanding biopharma ecosystem to drive market
  • 10.4.5 SOUTH KOREA
    • 10.4.5.1 Robust government support to expand oligonucleotide CDMO sector
  • 10.4.6 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Strong research institutions and growing collaboration between academia and industry to support market growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Rapidly advancing pharmaceutical and biotechnology sectors to fuel growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 RISING INVESTMENTS IN HEALTHCARE AND GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 10.6.3 MACROECONOMIC OUTLOOK FOR AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN OLIGONUCLEOTIDE CDMO MARKET
• 11.3 REVENUE ANALYSIS, 2021-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Service type footprint
    • 11.5.5.4 Type footprint
    • 11.5.5.5 Application footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING
    • 11.6.5.1 Detailed list of key startups/SMES
    • 11.6.5.2 Competitive benchmarking of startups/SMEs
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
• 11.8 BRAND/SERVICE COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 DEALS
  • 11.9.2 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 BACHEM
    • 12.1.1.1 Business overview
    • 12.1.1.2 Services offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 THERMO FISHER SCIENTIFIC INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Services offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
      • 12.1.2.3.2 Expansions
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 AGILENT TECHNOLOGIES, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Services offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
      • 12.1.3.3.2 Expansions
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 WUXI APPTEC
    • 12.1.4.1 Business overview
    • 12.1.4.2 Services offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Expansions
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices made
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 MARAVAI LIFESCIENCES
    • 12.1.5.1 Business overview
    • 12.1.5.2 Services offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
  • 12.1.6 LONZA
    • 12.1.6.1 Business overview
    • 12.1.6.2 Services offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Deals
      • 12.1.6.3.2 Expansions
  • 12.1.7 EUROFINS SCIENTIFIC
    • 12.1.7.1 Business overview
    • 12.1.7.2 Services offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
      • 12.1.7.3.2 Expansions
  • 12.1.8 DANAHER CORPORATION
    • 12.1.8.1 Business overview
    • 12.1.8.2 Services offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Expansions
  • 12.1.9 GENSCRIPT
    • 12.1.9.1 Business overview
    • 12.1.9.2 Services offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Expansions
  • 12.1.10 SYNGENE INTERNATIONAL LIMITED
    • 12.1.10.1 Business overview
    • 12.1.10.2 Services offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Expansions
  • 12.1.11 EUROAPI
    • 12.1.11.1 Business overview
    • 12.1.11.2 Services offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
      • 12.1.11.3.2 Expansions
  • 12.1.12 AJINOMOTO CO., INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Services offered
  • 12.1.13 ST PHARM
    • 12.1.13.1 Business overview
    • 12.1.13.2 Services offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Expansions
      • 12.1.13.3.2 Other developments
  • 12.1.14 KANEKA CORPORATION
    • 12.1.14.1 Business overview
    • 12.1.14.2 Services offered
  • 12.1.15 POLYPEPTIDE GROUP
    • 12.1.15.1 Business overview
    • 12.1.15.2 Services offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Deals
  • 12.1.16 AURIGENE PHARMACEUTICAL SERVICES LTD.
    • 12.1.16.1 Business overview
    • 12.1.16.2 Services offered
  • 12.1.17 BIOSPRING
    • 12.1.17.1 Business overview
    • 12.1.17.2 Services offered
    • 12.1.17.3 Recent developments
      • 12.1.17.3.1 Service approvals
      • 12.1.17.3.2 Expansions
• 12.2 OTHER PLAYERS
  • 12.2.1 OLIGO FACTORY
  • 12.2.2 CORDEN PHARMA
  • 12.2.3 LGC BIOSEARCH TECHNOLOGIES
  • 12.2.4 BI0-SYNTHESIS, INC.
  • 12.2.5 MICROSYNTH
  • 12.2.6 SYNOLIGO BIOTECHNOLOGIES, INC.
  • 12.2.7 HONGENE BIOTECH CORPORATION
  • 12.2.8 SYLENTIS, S.A.
  • 12.2.9 CREATIVE BIOGENE

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS